Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 5/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.44 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31005798 | 1.00 | CTSK (0.47) | CTSKTYRCTSLCTSBCTSS | |
| SCHEMBL22804081 | 1.00 | CTSK (0.47) | CTSKTYRCTSLCTSBCTSS | |
| SCHEMBL27718876 | 1.00 | CTSK (0.47) | CTSKTYRCTSLCTSBCTSS | |
| SCHEMBL30460474 | 1.00 | CTSK (0.47) | CTSKTYRCTSLCTSBCTSS | |
| SCHEMBL10630925 | 0.92 | CAPN1 (0.47) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL10658422 | 0.92 | TYR (0.41) | CTSKTYRCTSLCTSBCTSS | |
| SCHEMBL10658398 | 0.92 | TYR (0.41) | CTSKTYRCTSLCTSBCTSS | |
| SCHEMBL30367329 | 0.89 | PNMT (0.40) | CTSKTYR | |
| SCHEMBL30146700 | 0.89 | PNMT (0.42) | CTSKCAPN1CAPN2 | |
| Lysine SCHEMBL28193040 | 0.89 | ACE (0.41) | CTSKTYRCTSLCAPN1CAPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119591674-A | Cyclohexapeptide and preparation method and application thereof | 陕西未来多肽生物科技有限公司 | 2025-03-11 | — | — | CN | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| US-20130316989-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | RESOLVYX PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | claimed |
| US-20110190242-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | RESOLVYX PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| WO-2010039529-A2 | COMPOSITIONS AND METHODS FOR THE TREAMENT OF INFLAMMATORY DISEASE | RESOLVYX PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | claimed |
| CN-100590068-C | Method for preparing primary amine carbon nano tube | UNIV TONGJI | 2010-02-17 | — | — | CN | claimed |
| CN-101177259-A | Method for preparing primary amine carbon nano tube | UNIV TONGJI (CN) | 2008-05-14 | — | — | CN | claimed |
| CN-119899305-A | Polypeptide solid-phase synthesis carrier and preparation method thereof | 西安蓝晓科技新材料股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119591674-A | Cyclohexapeptide and preparation method and application thereof | 陕西未来多肽生物科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119462839-A | GPC 3-targeting compound, radionuclide probe and application thereof | 中国医学科学院肿瘤医院深圳医院 | 2025-02-18 | — | — | CN | disclosed |
| CN-113801156-B | Protein tyrosine phosphatase selective inhibitor, application, preparation method and pharmaceutical composition | 北京大学 | 2022-11-15 | — | — | CN | disclosed |
| CN-114478708-A | Solid phase synthesis method of ganirelix fragment | 南京汉欣医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-111040020-B | Alkene thioether staple peptide and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-04-12 | — | — | CN | disclosed |
| EP-1288228-A1 | BMP-2-derived peptides having osteogenetic activity and osteogenetic accelerator containing the same | Nishimura, Yoshihiko (JP) | 2003-03-05 | — | — | EP | disclosed |
| EP-1006126-A2 | Osteogenic peptides | Nishimura, Yoshihiko (JP) | 2000-06-07 | — | — | EP | disclosed |
| EP-0295316-A2 | Antitumor amino acid and peptide derivatives of 1,4-bis[ (aminoalkyl and hydroxyaminoalkyl)- amino]-5,8 dihydroxyanthraquinones | AMERICAN CYANAMID COMPANY (US) | 1988-12-21 | — | — | EP | disclosed |
| US-4732970-A | Antitumor amino acid and peptide derivatives of 1,4-bis(aminoalkyl and hydroxy-aminoalkyl)amino)-5,8-dihydroxyanthraquinones | AMERICAN CYANAMID COMPANY (US) | 1988-03-22 | — | — | US | disclosed |
| EP-0037388-B1 | PHARMACEUTICAL FORMS, THEIR PREPARATION AND COMPOSITIONS CONTAINING THE SAME | INSTITUT INTERNATIONAL DE PATHOLOGIE CELLULAIRE ET MOLECULAIRE (BE) | 1984-12-12 | — | — | EP | disclosed |
| US-4376765-A | Medicaments, their preparation and compositions containing same | INSTITUT INTERNATIONAL DE PATHOLOGIE CELLULAIRE ET MOLECULAIRE (BE) | 1983-03-15 | — | — | US | disclosed |
| EP-0037388-A2 | Pharmaceutical forms, their preparation and compositions containing the same | INSTITUT INTERNATIONAL DE PATHOLOGIE CELLULAIRE ET MOLECULAIRE (BE) | 1981-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130316989-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | ALOX15B, ALOX12, ALOX15 | CTSK 993/4885TYR 1873/4885CTSL 1448/4885 |
| US-20110190242-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | ALOX15B, ALOX12, ALOX15 | CTSK 993/4885TYR 1873/4885CTSL 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.